The global organoids market is on track for remarkable expansion, with forecasts indicating a surge to USD 1,306.4 million by 2024. This growth is set to continue at an impressive compound annual growth rate (CAGR) of 11.3% over the next decade, propelling the market to an estimated USD 3,828.0 million by 2034, according to the latest industry analysis.
Organoids—miniaturized, simplified versions of organs created in vitro—are revolutionizing scientific and medical research. Unlike traditional 2D cell cultures and animal models, organoids provide a more biologically relevant alternative. These three-dimensional structures replicate the architecture and function of human organs, offering unprecedented opportunities for advancement in various fields.
The escalating demand for organoids is driven by their transformative potential across multiple applications, including pathogenesis studies, regenerative medicine, and drug discovery and testing. Their increasing use in clinical trials is unveiling new insights into disease mechanisms and paving the way for innovative therapeutic interventions.
Technological advancements are fueling this market growth. Enhanced maturity and complexity of organoids, made possible by innovations in bioreactors and vascularization techniques, are overcoming previous limitations related to size and nutrient supply. These advancements are facilitating the creation of more sophisticated organoid models, further accelerating their adoption in research and clinical applications.
As the organoids market continues to expand, it is set to revolutionize personalized medicine, drug discovery, and regenerative medicine. The sector promises new avenues for effective treatments and a deeper understanding of human biology, marking a significant leap forward in medical science.
Key Takeaways: Organoids Market
- The global organoids market is poised for significant growth, reaching USD 1,306.4 million in 2024 and projected to triple to USD 3,828.0 million by 2034, with a CAGR of 11.3%.
- Regional Leadership:
- USA: Strongest market with a projected CAGR of 7.5%, driven by high healthcare spending and investment in advanced medical technologies.
- China: Rapid expansion with a predicted CAGR of 17.5%, fueled by a booming biotechnology sector and international collaborations.
- Japan: Growing market with a projected CAGR of 15.8%, boosted by collaborations with global players for technological advancement.
- Europe: Steady growth across major economies: Canada (7.9%), Germany (9.2%), France (8.8%), and Italy (8.4%).
- Key Drivers: Advancements in biotechnology, increasing demand for drug development and disease modeling, and growing investments in research and development are propelling market growth.
Increased Interest in Organoids: Explore Our Detailed Report for Key Trends and Insights!
Competitive Landscape of the Organoids Industry:
Industry players in the organoids sector are increasingly collaborating with other companies to leverage their research capabilities and drive breakthrough discoveries. These partnerships provide a competitive edge for both parties by synergistically utilizing existing technologies and enhancing market reach.
Many research firms in the organoids market strive to obtain certifications and other forms of recognition to strengthen their brand value within the industry. Introducing novel products and expanding service portfolios are common strategies employed by these companies. Below are some recent developments in the organoid industry.
Recent Industry Developments in the Organoids Market:
- In June 2024, DefiniGEN and Atelerix successfully shipped in vitro liver models from the UK to a leading pharmaceutical company in the US. This collaboration combined DefiniGEN’s iPSC hepatocytes with Atelerix’s hydrogel preservation technology, ensuring sample stability and functionality during long-distance transport.
- In May 2024, Crown Bioscience and the Shanghai Model Organisms Center (SMOC) expanded their existing partnership to provide immuno-oncology platforms and services from Crown Bioscience’s facilities to clients worldwide.
- In April 2024, Crown Bioscience achieved dual accreditation from the College of American Pathologists (CAP) for its medical laboratory services, further establishing its leadership in the field.
Key Players of the Organoids Industry:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Corning Incorporated
- Charles River Laboratories
- STEMCELL Technologies Inc.
- UPM Biomedicals
- Emulate, Inc.
- MIMETAS
- InSphero
- Promega Corporation
- Crown Biosciences
- Nortis Bio
- HUB Organoids
- Cellesce Ltd.
- Lena Biosciences, Inc.
Organoids Market Segmentation:
By Source:
In terms of source, the industry is segregated into embryonic stem cells (ESCs), induced PSCs (iPSCs), and human adult stem cells (ASCs).
By Organs:
In terms of organs, the industry is segmented into stomach, intestine, liver, pancreas, lung, cardiac, heart, brain, kidney, and other organs.
By Application:
In terms of application, the industry is bifurcated into developmental biology, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others applications.
By End User:
In terms of end user, the industry is segmented into biopharmaceutical companies, contract research organizations, and academics and research institutes.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East, and Africa have been covered in the report.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
The global cell culture market development is set to grow at a CAGR of 4.7% during the projected period. The market value is projected to increase from USD 27,911.3 million in 2024 to USD 44,593.1 million by 2034.
The global 3D cell culture market demand is projected to be worth USD 1.26 billion in 2023. The market is likely to reach USD 3 billion by 2033. The market is further expected to surge at a CAGR of 9% during the forecast period 2023 to 2033.
The global cell culture incubator market size is expected to be valued at USD 2,315.5 million in 2023, and is projected to reach USD 4,305.1 million by 2033. A CAGR worth 6.4% is expected for the market during the 2023 to 2033 forecast period.
The global dehydrated culture media market share is forecast to grow at a 7.7% CAGR from 2023 to 2033. As per its findings, a valuation of USD 4 billion is expected as of 2023, and will ultimately reach USD 8.4 billion by 2033.
The global cell culture sampling devices market overview is anticipated to flourish at a steady CAGR of 10.8% between 2023 and 2033. The market is expected to hold a market share of USD 7.80 billion by 2033, while the market is likely to reach a value of USD 2.79 billion in 2023.
The global automated cell culture systems market growth is projected to increase from a valuation of USD 10.91 Billion in 2022 to USD 20.87 Billion by 2030.
The global intravenous pegloticase market trends with a slowly progressing CAGR of 13.8% from 2023 to 2033, this market is expected to garner USD 3.19 Billion by 2023 and USD 11.61 Billion by 2033.
The global photoacoustic microscopy market opportunity is likely to hit the USD 120 billion valuation mark by 2024. Owing to an impressive CAGR of 17.3% through 2034, the ecosystem is set to reach USD 591.6 million by the end of the forecast period.
The global cell culture media bag market outlook is expected to be valued at USD 1,308.7 million in 2023 and to reach a valuation of USD 3,541 million by 2033. The demand for cell culture media bag is estimated to grow at a steady 10.5% CAGR.
The global intravenous iron drugs market forecast is projected to reach USD 2.8 Billion in 2022 and is expected to growth USD 6.3 Billion by 2032 at a CAGR of 8.5%.
The global venous stents market strategies valued at approximately USD 990.5 million in 2023, is expected to soar to an impressive USD 2.2 billion by the end of 2033. This growth represents a substantial compound annual growth rate (CAGR) of 8.4% from 2023 to 2033.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube